
Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter. In Q3, CRISPR Therapeutics brought in $824.00 thousand in sales but lost $127.15 million in earnings.